Last reviewed · How we verify

Poisoning by digitalis glycoside — Treatment Landscape & Competitive Intelligence

Poisoning by digitalis glycoside (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Poisoning by digitalis glycoside, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lanoxin digoxin Generic (originally Burroughs Wellcome/GSK) Cardiac Glycoside [EPC] Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2 1954-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Burroughs Wellcome/GSK) · 1 drug in Poisoning by digitalis glycoside

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Poisoning by digitalis glycoside:

Cite this brief

Drug Landscape (2026). Poisoning by digitalis glycoside — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/poisoning-by-digitalis-glycoside. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing